Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Spero Therapeutics stock price, quote, forecast and news

SPRO
US84833T1034
A2H63F

Price

1.37
Today +/-
+0.05
Today %
+4.10 %
P

Spero Therapeutics stock price

%
Weekly
Details

Price

Overview

The Quote Chart provides detailed and dynamic insights into the Spero Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Spero Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Spero Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Spero Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Spero Therapeutics Stock Price History

DateSpero Therapeutics Price
9/9/20241.37 undefined
9/6/20241.32 undefined
9/5/20241.33 undefined
9/4/20241.31 undefined
9/3/20241.34 undefined
8/30/20241.37 undefined
8/29/20241.37 undefined
8/28/20241.37 undefined
8/27/20241.38 undefined
8/26/20241.36 undefined
8/23/20241.37 undefined
8/22/20241.35 undefined
8/21/20241.37 undefined
8/20/20241.25 undefined
8/19/20241.27 undefined
8/16/20241.19 undefined
8/15/20241.21 undefined
8/14/20241.22 undefined
8/13/20241.27 undefined
8/12/20241.29 undefined

Spero Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into Spero Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Spero Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Spero Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Spero Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Spero Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Spero Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Spero Therapeutics’s growth potential.

Spero Therapeutics Revenue, EBIT and net profit per share

DateSpero Therapeutics RevenueSpero Therapeutics EBITSpero Therapeutics Net Income
2029e138.72 M undefined0 undefined26.46 M undefined
2028e134.23 M undefined46.41 M undefined30.32 M undefined
2027e82.26 M undefined-12.24 M undefined-11.58 M undefined
2026e19.13 M undefined-41.92 M undefined-77.18 M undefined
2025e18.87 M undefined-74.83 M undefined-73.32 M undefined
2024e19.74 M undefined-72.79 M undefined-73.46 M undefined
2023103.78 M undefined26.79 M undefined22.81 M undefined
202253.51 M undefined-30.57 M undefined-46.42 M undefined
202118.26 M undefined-87.97 M undefined-89.76 M undefined
20209.33 M undefined-79.11 M undefined-78.83 M undefined
201918.15 M undefined-63.22 M undefined-60.93 M undefined
20183.97 M undefined-42.81 M undefined-41.66 M undefined
20171.98 M undefined-41.73 M undefined-46.1 M undefined
2016340,000 undefined-33.22 M undefined-29.93 M undefined
20150 undefined-13.33 M undefined-13.43 M undefined

Spero Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0013189185310319181982134138
---200.00500.00-50.00100.00194.4494.34-81.55-5.265.56331.5863.412.99
---------------
000000000000000
-13-33-41-42-63-79-87-3026-72-74-41-12460
---4,100.00-1,400.00-350.00-877.78-483.33-56.6025.24-378.95-411.11-215.79-14.6334.33-
-13-29-46-41-60-78-89-4622-73-73-77-113026
-123.0858.62-10.8746.3430.0014.10-48.31-147.83-431.82-5.48-85.71-372.73-13.33
13.913.914.371618.1622.3930.937.5952.99000000
---------------
Details

Keystats

Revenue and Growth

The Spero Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Spero Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201520162017201820192020202120222023
                 
5.710.387.3115.482126.9146.4109.176.33
000000000
000000000
000000000
0.31.31.87.54.86.18.83.44.18
611.689.1122.986.8133155.2112.580.51
0.91.51.22.97.18.87.65.54.16
000000000
00.100.200.30046.59
000000000
000000000
0.20.30.31.73.55.25.65.70.44
1.11.91.54.810.614.313.211.251.18
7.113.590.6127.797.4147.3168.4123.7131.69
                 
18.355.6000000.10.05
00181.4254274409.7455.7489.8497.91
-18.1-45.4-96.8-138.5-199.4-277.7-367.5-413.9-391.07
000000000
000000000
0.210.284.6115.574.613288.276106.89
1.81.13.53.64.11.21.10.61.38
0.62.94.38.322.513.215.710.78.28
42.90.40.5001.910.427.5
000000000
000000000
6.46.98.212.426.614.418.721.737.15
00000048.400
000000000
10.50.40.84.97.115.727.238.34
10.50.40.84.97.164.127.238.34
7.47.48.613.231.521.582.848.975.5
7.617.693.2128.7106.1153.5171124.9182.39
Details

Balance Sheet

Understanding the Balance Sheet

The balance sheet of Spero Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Spero Therapeutics's financial health and stability.

Assets

Spero Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Spero Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Spero Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Spero Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201520162017201820192020202120222023
-13-32-39-41-60-78-89-4622
000000000
000000000
000-16-131222-70
340235111514
000000000
000000002
-9-28-39-39-50-85-64-7-32
000-200000
000-8329107330
000-8029107330
000000000
0000000-540
1534120701613136240
1534116691613084-290
00-4-1004700
000000000
5476-53-45527-3-32
-9.84-29.79-39.14-42.07-50.33-86.03-64.35-7.73-33
000000000

Spero Therapeutics stock margins

The Spero Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Spero Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Spero Therapeutics.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Spero Therapeutics's sales revenue. A higher gross margin percentage indicates that the Spero Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Spero Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Spero Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Spero Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Spero Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Spero Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Spero Therapeutics Margin History

Spero Therapeutics Gross marginSpero Therapeutics Profit marginSpero Therapeutics EBIT marginSpero Therapeutics Profit margin
2029e0 %0 %19.08 %
2028e0 %34.57 %22.59 %
2027e0 %-14.88 %-14.07 %
2026e0 %-219.2 %-403.57 %
2025e0 %-396.58 %-388.58 %
2024e0 %-368.79 %-372.2 %
20230 %25.81 %21.98 %
20220 %-57.13 %-86.75 %
20210 %-481.76 %-491.57 %
20200 %-847.91 %-844.91 %
20190 %-348.32 %-335.7 %
20180 %-1,078.34 %-1,049.37 %
20170 %-2,107.58 %-2,328.28 %
20160 %-9,770.59 %-8,802.94 %
20150 %0 %0 %

Spero Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Spero Therapeutics earnings per share therefore indicates how much revenue Spero Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Spero Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Spero Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Spero Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Spero Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Spero Therapeutics Revenue, EBIT and net profit per share

DateSpero Therapeutics Sales per ShareSpero Therapeutics EBIT per shareSpero Therapeutics Earnings per Share
2029e2.57 undefined0 undefined0.49 undefined
2028e2.48 undefined0 undefined0.56 undefined
2027e1.52 undefined0 undefined-0.21 undefined
2026e0.35 undefined0 undefined-1.43 undefined
2025e0.35 undefined0 undefined-1.36 undefined
2024e0.37 undefined0 undefined-1.36 undefined
20231.96 undefined0.51 undefined0.43 undefined
20221.42 undefined-0.81 undefined-1.23 undefined
20210.59 undefined-2.85 undefined-2.9 undefined
20200.42 undefined-3.53 undefined-3.52 undefined
20191 undefined-3.48 undefined-3.36 undefined
20180.25 undefined-2.68 undefined-2.6 undefined
20170.14 undefined-2.9 undefined-3.21 undefined
20160.02 undefined-2.39 undefined-2.15 undefined
20150 undefined-0.96 undefined-0.97 undefined

Spero Therapeutics business model

Spero Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of novel antibiotics for the treatment of serious infections. The company was founded in 2013 and is based in Cambridge, Massachusetts. Spero Therapeutics is one of the most popular companies on Eulerpool.com.

Spero Therapeutics SWOT Analysis

Strengths

Spero Therapeutics Inc has several strengths that contribute to its competitive advantage:

  • Strong pipeline: Spero Therapeutics Inc has a robust pipeline of innovative drug candidates, providing potential for future growth and revenue.
  • Experienced management team: The company is led by a highly skilled management team with extensive industry knowledge and expertise.
  • Strategic partnerships: Spero Therapeutics Inc has established strategic partnerships with leading pharmaceutical companies, enhancing its research capabilities and market reach.
  • Patent portfolio: The company holds a strong patent portfolio, providing protection for its intellectual property and reducing the threat of competition.
  • Financial stability: Spero Therapeutics Inc has a solid financial position, with sufficient funds to support its operations and research activities.

Weaknesses

Despite its strengths, Spero Therapeutics Inc also faces certain weaknesses that need to be addressed:

  • Dependence on limited drug candidates: The success of Spero Therapeutics Inc heavily relies on the performance of its limited drug candidates, making it vulnerable to failure or delays in clinical trials.
  • Relatively small market share: As a smaller player in the pharmaceutical industry, Spero Therapeutics Inc may face challenges in competing with larger, more established companies.
  • Regulatory hurdles: The company operates in a highly regulated industry, and any delays or difficulties in obtaining necessary approvals may hinder the progress of its drug candidates.
  • Resource constraints: Spero Therapeutics Inc may face resource constraints, including limited financial resources and a smaller workforce compared to its competitors.

Opportunities

Spero Therapeutics Inc can capitalize on the following opportunities to drive future growth:

  • Market demand for new antibiotics: With the increasing prevalence of antibiotic-resistant infections, there is a growing demand for innovative antibiotics, presenting a significant market opportunity for Spero Therapeutics Inc.
  • Expanding partnerships: The company can further expand its strategic partnerships to access additional resources, expertise, and market opportunities.
  • Global market expansion: Spero Therapeutics Inc has the potential to expand its market presence globally and cater to the growing healthcare needs in different regions.
  • Advancements in technology: Rapid advancements in technology, such as genomics and data analytics, could provide new insights and opportunities for drug discovery and development, which Spero Therapeutics Inc can leverage.

Threats

Spero Therapeutics Inc faces certain threats that could impede its growth prospects:

  • Intense competition: The pharmaceutical industry is highly competitive, with numerous established players and emerging biotech companies vying for market share, which may restrict Spero Therapeutics Inc's ability to gain significant market traction.
  • Regulatory challenges: Changes in regulations or stringent regulatory requirements can add complexity and delays to the drug development process, impacting Spero Therapeutics Inc's ability to bring its products to market.
  • Uncertain reimbursement landscape: The reimbursement landscape for pharmaceutical products is subject to changes and uncertainties, potentially affecting the pricing and profitability of Spero Therapeutics Inc's drugs.
  • Pandemic-related disruptions: The ongoing COVID-19 pandemic can disrupt clinical trials, supply chains, and healthcare systems, posing challenges and delays for Spero Therapeutics Inc.

Spero Therapeutics Eulerpool Fair Value

Details

Fair Value

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Spero Therapeutics historical P/E ratio, EBIT, and P/S ratio.

Spero Therapeutics shares outstanding

The number of shares was Spero Therapeutics in 2023 — This indicates how many shares 52.989 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Spero Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Spero Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Spero Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Spero Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Spero Therapeutics dividend history and estimates

In 2023, Spero Therapeutics paid a dividend amounting to 0 USD. Dividend means that Spero Therapeutics distributes a portion of its profits to its owners.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

Dividend Overview

The dividend per year chart for Spero Therapeutics provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Spero Therapeutics’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Spero Therapeutics's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Spero Therapeutics Dividend History

DateSpero Therapeutics Dividend
20150.05 undefined

Spero Therapeutics dividend payout ratio

In 2023, Spero Therapeutics had a payout ratio of 0%. The payout ratio indicates the percentage of the company's profits that Spero Therapeutics distributes as dividends.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

What is Yearly Payout Ratio?

The yearly payout ratio for Spero Therapeutics represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Spero Therapeutics could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Spero Therapeutics's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Spero Therapeutics Payout Ratio History

DateSpero Therapeutics Payout ratio
2029e0 %
2028e0 %
2027e0 %
2026e0 %
2025e0 %
2024e0 %
20230 %
20220 %
20210 %
20200 %
20190 %
20180 %
20170 %
20160 %
2015-4.64 %
Unfortunately, there are currently no price targets and forecasts available for Spero Therapeutics.

Spero Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.39 -0.33  (14.86 %)2024 Q2
3/31/2024-0.04 -0.24  (-442.99 %)2024 Q1
12/31/2023-0.1 0.96  (1,041.18 %)2023 Q4
9/30/2023-0.03 0.04  (230.72 %)2023 Q3
6/30/2023-0.35 -0.23  (34.32 %)2023 Q2
3/31/2023-0.34 -0.25  (26.47 %)2023 Q1
12/31/20220.04 0.55  (1,144.34 %)2022 Q4
9/30/2022-0.31 -0.33  (-6.66 %)2022 Q3
6/30/2022-0.95 -0.87  (7.96 %)2022 Q2
3/31/2022-0.89 -1.01  (-13.91 %)2022 Q1
1
2
3

Eulerpool ESG Scorecard© for the Spero Therapeutics stock

Eulerpool World ESG Rating (EESG©)

51/ 100

🌱 Environment

48

👫 Social

55

🏛️ Governance

51

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Spero Therapeutics list of shareholders

%
Name
Stocks
Change
Date
7.95134 % Anson Funds Management LP.4,297,699138,12712/31/2023
3.04118 % The Vanguard Group, Inc.1,643,75786,16112/31/2023
17.00390 % GSK plc9,190,60603/8/2024
1.97541 % Adar1 Capital Management LLC1,067,7111,067,71112/31/2023
1.87500 % Atlas Venture1,013,438-1,353,30312/31/2023
1.64658 % Alphabet, Inc.889,979012/31/2023
1.59611 % Murchinson Ltd.862,700012/31/2023
1.45813 % Hamed (Kamal)788,117211,6562/2/2024
1.01289 % Renaissance Technologies LLC547,46530012/31/2023
0.86889 % BlackRock Institutional Trust Company, N.A.469,635-1,18412/31/2023
1
2
3
4
5
...
10

Spero Therapeutics Executives and Management Board

Dr. Ankit Mahadevia42
Spero Therapeutics Chairman of the Board (since 2015)
Compensation 4.24 M
Mr. Satyavrat Shukla51
Spero Therapeutics President, Chief Executive Officer, Director (since 2021)
Compensation 1.67 M
Ms. Tamara Joseph60
Spero Therapeutics Chief Legal Officer, Corporate Secretary
Compensation 1.63 M
Dr. Milind Deshpande67
Spero Therapeutics Independent Director
Compensation 109,550
Dr. Patrick Vink60
Spero Therapeutics Lead Independent Director
Compensation 84,566
1
2
3

Spero Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
SupplierCustomer0,84-0,530,580,730,630,10
SupplierCustomer-0,740,33-0,15-0,74-0,89-0,58
SupplierCustomer-0,890,100,350,830,72-
1

Most common questions regarding Spero Therapeutics

What values and corporate philosophy does Spero Therapeutics represent?

Spero Therapeutics Inc is a pharmaceutical company that focuses on developing novel treatments for serious infections. The company's corporate philosophy is centered around innovation, collaboration, and patient-centricity. By embracing cutting-edge science and fostering collaborations with leading researchers, Spero Therapeutics Inc aims to address the significant unmet medical needs in the field of infectious diseases. Their values include a commitment to scientific excellence, dedication to patient well-being, and a passion for improving global public health. Through their research and development efforts, Spero Therapeutics Inc strives to make a positive impact on the lives of patients and revolutionize the treatment landscape for infectious diseases.

In which countries and regions is Spero Therapeutics primarily present?

Spero Therapeutics Inc is primarily present in the United States.

What significant milestones has the company Spero Therapeutics achieved?

Spero Therapeutics Inc, a leading biopharmaceutical company, has achieved remarkable milestones in its journey. The company successfully completed a Phase 1 clinical trial for its novel product candidate, SPR206, designed to combat multi-drug resistant infections. Additionally, Spero Therapeutics Inc received a contract from the Biomedical Advanced Research and Development Authority (BARDA) for the development of SPR720, an oral antibiotic. These accomplishments reinforce Spero Therapeutics Inc's commitment to addressing unmet medical needs and delivering innovative solutions for patients. Through their unwavering dedication and cutting-edge research, Spero Therapeutics Inc continues to make substantial strides in the field of antibacterial therapy.

What is the history and background of the company Spero Therapeutics?

Spero Therapeutics Inc is a pharmaceutical company focused on developing novel treatments for drug-resistant bacterial infections. Founded in 2013, the company is headquartered in Cambridge, Massachusetts. Spero Therapeutics is dedicated to addressing the urgent global need for effective antibiotics, as the rise of antibiotic resistance has become a major public health concern. The company utilizes its proprietary platform to identify and develop potent drugs that target a wide range of bacteria. By harnessing innovative science and advanced research, Spero Therapeutics aims to provide hope for patients suffering from serious and life-threatening infections.

Who are the main competitors of Spero Therapeutics in the market?

Some of the main competitors of Spero Therapeutics Inc in the market include biopharmaceutical companies like Merck & Co., Inc., Pfizer Inc., and GlaxoSmithKline plc. These competitors are also engaged in researching and developing innovative therapies for infectious diseases, with a focus on combating drug-resistant bacteria.

In which industries is Spero Therapeutics primarily active?

Spero Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Spero Therapeutics?

The business model of Spero Therapeutics Inc is centered around developing and commercializing novel treatments for multi-drug-resistant bacterial infections. They aim to address the urgent need for new antibiotics to combat the growing threat of antibiotic resistance. Spero Therapeutics Inc utilizes its platform, including its proprietary Potentiator Platform, to discover and design potential drugs that can enhance the therapeutic efficacy of existing antibiotics and overcome resistance mechanisms. By focusing on serious bacterial infections that have limited treatment options, Spero Therapeutics Inc strives to provide better healthcare solutions for patients in need.

What is the P/E ratio of Spero Therapeutics 2024?

The Spero Therapeutics P/E ratio is -0.99.

What is the P/S ratio of Spero Therapeutics 2024?

The Spero Therapeutics P/S ratio is 3.68.

What is the AlleAktien quality score of Spero Therapeutics?

The AlleAktien quality score for Spero Therapeutics is 4/10.

What is the revenue of Spero Therapeutics 2024?

The expected Spero Therapeutics revenue is 19.74 M USD.

How high is the profit of Spero Therapeutics 2024?

The expected Spero Therapeutics profit is -73.46 M USD.

What is the business model of Spero Therapeutics

Spero Therapeutics Inc. is a biopharmaceutical company focused on the development of new antibiotics to combat antibiotic resistance. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

What is the Spero Therapeutics dividend?

Spero Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Spero Therapeutics pay dividends?

The dividend cannot currently be calculated for Spero Therapeutics or the company does not pay out a dividend.

What is the Spero Therapeutics ISIN?

The ISIN of Spero Therapeutics is US84833T1034.

What is the Spero Therapeutics WKN?

The WKN of Spero Therapeutics is A2H63F.

What is the Spero Therapeutics ticker?

The ticker of Spero Therapeutics is SPRO.

How much dividend does Spero Therapeutics pay?

Over the past 12 months, Spero Therapeutics paid a dividend of 0.05 USD . This corresponds to a dividend yield of about 3.28 %. For the coming 12 months, Spero Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Spero Therapeutics?

The current dividend yield of Spero Therapeutics is 3.28 %.

When does Spero Therapeutics pay dividends?

Spero Therapeutics pays a quarterly dividend. This is distributed in the months of April, April, July, October.

How secure is the dividend of Spero Therapeutics?

Spero Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Spero Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Spero Therapeutics located?

Spero Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Spero Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Spero Therapeutics from 10/7/2015 amounting to 0.015 USD, you needed to have the stock in your portfolio before the ex-date on 9/16/2015.

When did Spero Therapeutics pay the last dividend?

The last dividend was paid out on 10/7/2015.

What was the dividend of Spero Therapeutics in the year 2023?

In the year 2023, Spero Therapeutics distributed 0 USD as dividends.

In which currency does Spero Therapeutics pay out the dividend?

The dividends of Spero Therapeutics are distributed in USD.

All fundamentals about Spero Therapeutics

Our stock analysis for Spero Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Spero Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.